stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) EV/FCF
As of 5 November 2026, Tarsus Pharmaceuticals, Inc. (TARS) trades at a EV/FCF of 124×. Over the past ten years it has ranged from −756× (April 2022) to 146× (September 2026); the current reading is higher than 98% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −98.2× | — |
| FY2024 | −19.9× | — |
| FY2023 | −3.3× | — |
| FY2022 | −3.2× | — |
| FY2021 | 92.1× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 146× | 190.64% |
| Jun 2026 | 50.1× | — |
| Mar 2026 | −66.5× | — |
| Dec 2025 | −98.2× | — |
| 17 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | −73.9× |
| ELVN Enliven Therapeutics, Inc. compare | −31.3× |
| ACAD ACADIA Pharmaceuticals Inc. compare | −23.3× |
| CELC Celcuity, Inc. compare | −18.4× |
| DNLI Denali Therapeutics Inc. compare | −7.2× |
| VRDN Viridian Therapeutics, Inc. compare | −7.0× |
| VKTX Viking Therapeutics, Inc. compare | −5.1× |
| DYN Dyne Therapeutics, Inc. compare | −4.6× |
| TARS Tarsus Pharmaceuticals, Inc. | 124× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement